From Target to Clinic – Development & Manufacturing of the First in Class VARTUMAB ADC
2:02 pm - Tuesday 9th March 2027
- Oncofetal chondroitin sulfate, an abundant pan-cancer target present on cancer cells and in the tumor stroma
- Selection of a monovalent scFv–Fc VARTUMAB ADC format, enabling a homogeneous DAR2 construct with deep tumor penetration and potent bystander activity
- GMP manufacturing and control of VARTUMAB ADC achieving high yield, purity and stability
